Correlation of PSA and Survival in Metastatic Hormone-Sensitive Prostate Cancer Treated with Rezvilutamide plus ADT in the CHART Trial

Researchers conducted an exploratory analysis of the CHART trial which investigated prostate-specific antigen (PSA) kinetics and the correlation between PSA and survival outcomes in high-volume, metastatic, hormone-sensitive prostate cancer.